ParkinsonCanadaV1, PascalFrancis, Corpus, bibRecord, 000E21

Levodopa improves motor function without impairing cognition in mild nondemented Parkinson's disease patients

Identifieur interne : 000E21 ( PascalFrancis/Corpus ); précédent : 000E20; suivant : 000E22

Levodopa improves motor function without impairing cognition in mild nondemented Parkinson's disease patients

Auteurs : J. H. Growdon ; K. Kieburtz ; M. P. Mcdermott ; M. Panisset ; J. H. Friedman

Source :

Neurology [ 0028-3878 ] ; 1998.

RBID : Pascal:98-0273419

Descripteurs français

Pascal (Inist)
- Parkinson maladie, Lévodopa, Antiparkinsonien, Cognition, Motricité, Psychométrie, Chimiothérapie, Traitement, Homme.

English descriptors

KwdEn :
- Antiparkinson agent, Chemotherapy, Cognition, Human, Levodopa, Motricity, Parkinson disease, Psychometrics, Treatment.

Abstract

Article abstract-Objective: The objective of the study was to determine the effects of short-term levodopa administration on motor, cognitive, and psychiatric aspects of Parkinson's disease (PD). Background: The effects of levodopa on mental processes in PD are controversial. Opinions range from the claim that levodopa improves cognition to the opposite view that levodopa causes or exacerbates dementia, delusions, and hallucinations. Of the 800 idiopathic PD patients enrolled in the original DATATOP study, 387 reached the end point of functional disabilities sufficiently severe to require levodopa treatment. There were 263 men and 124 women who were comparable with regard to age, symptom duration of PD, and measures of PD severity. We compared test scores on motor performance, cognitive function, and psychiatric status before levodopa and again within 6 months after initiation of levodopa therapy. Results: Levodopa administration improved all motor functions significantly. The improvement was significantly greater in women than in men. Levodopa administration did not worsen scores on any cognitive tests, and there were quantitatively small but significant improvements in tests of frontal lobe function. Levodopa exerted only minor effects on psychiatric measures. There were small but significant decreases in scores for depression, and increases in vivid dreams and hallucinations. Conclusions: Levodopa administration for up to 6 months in dosages sufficient to improve motor function has only small effects on cognitive function and psychiatric status in mild to moderate PD patients. We conclude that motor symptoms in early PD, which result from dopamine depletion, are dissociable from cognitive functions and psychiatric status, which may be more dependent on nondopaminergic mechanisms.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0028-3878`
A02	`01`			`@0 NEURAI`
A03		`1`		`@0 Neurology`
A05				`@2 50`
A06				`@2 5`
A08	`01`	`1`	`ENG`	`@1 Levodopa improves motor function without impairing cognition in mild nondemented Parkinson's disease patients`
A11	`01`	`1`		`@1 GROWDON (J. H.)`
A11	`02`	`1`		`@1 KIEBURTZ (K.)`
A11	`03`	`1`		`@1 MCDERMOTT (M. P.)`
A11	`04`	`1`		`@1 PANISSET (M.)`
A11	`05`	`1`		`@1 FRIEDMAN (J. H.)`
A14	`01`			`@1 Massachusetts General Hospital @2 Boston @3 USA @Z 1 aut.`
A14	`02`			`@1 Department of Neurology, University of Rochester @2 NY @3 CAN @Z 2 aut.`
A14	`03`			`@1 Department of Biostatistics, University of Rochester @2 NY @3 CAN @Z 3 aut.`
A14	`04`			`@1 McGill Centre for Studies in Aging @2 Verdun, Quebec @3 CAN @Z 4 aut.`
A14	`05`			`@1 Department of Neurology, Memorial Hospital of Rhode Island @2 Pawtucket @3 USA @Z 5 aut.`
A17	`01`	`1`		`@1 Parkinson Study Group @3 USA`
A20				`@1 1327-1331`
A21				`@1 1998`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 6345 @5 354000075877600220`
A44				`@0 0000 @1 © 1998 INIST-CNRS. All rights reserved.`
A45				`@0 29 ref.`
A47	`01`	`1`		`@0 98-0273419`
A60				`@1 P`
A61				`@0 A`
A64		`1`		`@0 Neurology`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Article abstract-Objective: The objective of the study was to determine the effects of short-term levodopa administration on motor, cognitive, and psychiatric aspects of Parkinson's disease (PD). Background: The effects of levodopa on mental processes in PD are controversial. Opinions range from the claim that levodopa improves cognition to the opposite view that levodopa causes or exacerbates dementia, delusions, and hallucinations. Of the 800 idiopathic PD patients enrolled in the original DATATOP study, 387 reached the end point of functional disabilities sufficiently severe to require levodopa treatment. There were 263 men and 124 women who were comparable with regard to age, symptom duration of PD, and measures of PD severity. We compared test scores on motor performance, cognitive function, and psychiatric status before levodopa and again within 6 months after initiation of levodopa therapy. Results: Levodopa administration improved all motor functions significantly. The improvement was significantly greater in women than in men. Levodopa administration did not worsen scores on any cognitive tests, and there were quantitatively small but significant improvements in tests of frontal lobe function. Levodopa exerted only minor effects on psychiatric measures. There were small but significant decreases in scores for depression, and increases in vivid dreams and hallucinations. Conclusions: Levodopa administration for up to 6 months in dosages sufficient to improve motor function has only small effects on cognitive function and psychiatric status in mild to moderate PD patients. We conclude that motor symptoms in early PD, which result from dopamine depletion, are dissociable from cognitive functions and psychiatric status, which may be more dependent on nondopaminergic mechanisms.
C02	`01`	`X`		`@0 002B02B06`
C03	`01`	`X`	`FRE`	`@0 Parkinson maladie @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @5 01`
C03	`02`	`X`	`FRE`	`@0 Lévodopa @5 04`
C03	`02`	`X`	`ENG`	`@0 Levodopa @5 04`
C03	`02`	`X`	`SPA`	`@0 Levodopa @5 04`
C03	`03`	`X`	`FRE`	`@0 Antiparkinsonien @5 05`
C03	`03`	`X`	`ENG`	`@0 Antiparkinson agent @5 05`
C03	`03`	`X`	`SPA`	`@0 Antiparkinsoniano @5 05`
C03	`04`	`X`	`FRE`	`@0 Cognition @5 07`
C03	`04`	`X`	`ENG`	`@0 Cognition @5 07`
C03	`04`	`X`	`SPA`	`@0 Cognición @5 07`
C03	`05`	`X`	`FRE`	`@0 Motricité @5 10`
C03	`05`	`X`	`ENG`	`@0 Motricity @5 10`
C03	`05`	`X`	`SPA`	`@0 Motricidad @5 10`
C03	`06`	`X`	`FRE`	`@0 Psychométrie @5 13`
C03	`06`	`X`	`ENG`	`@0 Psychometrics @5 13`
C03	`06`	`X`	`SPA`	`@0 Psicometría @5 13`
C03	`07`	`X`	`FRE`	`@0 Chimiothérapie @5 16`
C03	`07`	`X`	`ENG`	`@0 Chemotherapy @5 16`
C03	`07`	`X`	`SPA`	`@0 Quimioterapia @5 16`
C03	`08`	`X`	`FRE`	`@0 Traitement @5 17`
C03	`08`	`X`	`ENG`	`@0 Treatment @5 17`
C03	`08`	`X`	`GER`	`@0 Aufbereiten @5 17`
C03	`08`	`X`	`SPA`	`@0 Tratamiento @5 17`
C03	`09`	`X`	`FRE`	`@0 Homme @5 20`
C03	`09`	`X`	`ENG`	`@0 Human @5 20`
C03	`09`	`X`	`SPA`	`@0 Hombre @5 20`
C07	`01`	`X`	`FRE`	`@0 Système nerveux pathologie @5 37`
C07	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 37`
C07	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 38`
C07	`02`	`X`	`ENG`	`@0 Central nervous system disease @5 38`
C07	`02`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 38`
C07	`03`	`X`	`FRE`	`@0 Encéphale pathologie @5 39`
C07	`03`	`X`	`ENG`	`@0 Cerebral disorder @5 39`
C07	`03`	`X`	`SPA`	`@0 Encéfalo patología @5 39`
C07	`04`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 40`
C07	`04`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 40`
C07	`04`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 40`
C07	`05`	`X`	`FRE`	`@0 Maladie dégénérative @5 41`
C07	`05`	`X`	`ENG`	`@0 Degenerative disease @5 41`
C07	`05`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 41`
N21				`@1 180`

Format Inist (serveur)

NO :	PASCAL 98-0273419 INIST
ET :	Levodopa improves motor function without impairing cognition in mild nondemented Parkinson's disease patients
AU :	GROWDON (J. H.); KIEBURTZ (K.); MCDERMOTT (M. P.); PANISSET (M.); FRIEDMAN (J. H.)
AF :	Massachusetts General Hospital/Boston/Etats-Unis (1 aut.); Department of Neurology, University of Rochester/NY/Canada (2 aut.); Department of Biostatistics, University of Rochester/NY/Canada (3 aut.); McGill Centre for Studies in Aging/Verdun, Quebec/Canada (4 aut.); Department of Neurology, Memorial Hospital of Rhode Island/Pawtucket/Etats-Unis (5 aut.)
DT :	Publication en série; Niveau analytique
SO :	Neurology; ISSN 0028-3878; Coden NEURAI; Etats-Unis; Da. 1998; Vol. 50; No. 5; Pp. 1327-1331; Bibl. 29 ref.
LA :	Anglais
EA :	Article abstract-Objective: The objective of the study was to determine the effects of short-term levodopa administration on motor, cognitive, and psychiatric aspects of Parkinson's disease (PD). Background: The effects of levodopa on mental processes in PD are controversial. Opinions range from the claim that levodopa improves cognition to the opposite view that levodopa causes or exacerbates dementia, delusions, and hallucinations. Of the 800 idiopathic PD patients enrolled in the original DATATOP study, 387 reached the end point of functional disabilities sufficiently severe to require levodopa treatment. There were 263 men and 124 women who were comparable with regard to age, symptom duration of PD, and measures of PD severity. We compared test scores on motor performance, cognitive function, and psychiatric status before levodopa and again within 6 months after initiation of levodopa therapy. Results: Levodopa administration improved all motor functions significantly. The improvement was significantly greater in women than in men. Levodopa administration did not worsen scores on any cognitive tests, and there were quantitatively small but significant improvements in tests of frontal lobe function. Levodopa exerted only minor effects on psychiatric measures. There were small but significant decreases in scores for depression, and increases in vivid dreams and hallucinations. Conclusions: Levodopa administration for up to 6 months in dosages sufficient to improve motor function has only small effects on cognitive function and psychiatric status in mild to moderate PD patients. We conclude that motor symptoms in early PD, which result from dopamine depletion, are dissociable from cognitive functions and psychiatric status, which may be more dependent on nondopaminergic mechanisms.
CC :	002B02B06
FD :	Parkinson maladie; Lévodopa; Antiparkinsonien; Cognition; Motricité; Psychométrie; Chimiothérapie; Traitement; Homme
FG :	Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative
ED :	Parkinson disease; Levodopa; Antiparkinson agent; Cognition; Motricity; Psychometrics; Chemotherapy; Treatment; Human
EG :	Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease
GD :	Aufbereiten
SD :	Parkinson enfermedad; Levodopa; Antiparkinsoniano; Cognición; Motricidad; Psicometría; Quimioterapia; Tratamiento; Hombre
LO :	INIST-6345.354000075877600220
ID :	98-0273419

Links to Exploration step

Pascal:98-0273419

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Levodopa improves motor function without impairing cognition in mild nondemented Parkinson's disease patients</title>
<author><name sortKey="Growdon, J H" sort="Growdon, J H" uniqKey="Growdon J" first="J. H." last="Growdon">J. H. Growdon</name>
<affiliation><inist:fA14 i1="01"><s1>Massachusetts General Hospital</s1>
<s2>Boston</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kieburtz, K" sort="Kieburtz, K" uniqKey="Kieburtz K" first="K." last="Kieburtz">K. Kieburtz</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Neurology, University of Rochester</s1>
<s2>NY</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mcdermott, M P" sort="Mcdermott, M P" uniqKey="Mcdermott M" first="M. P." last="Mcdermott">M. P. Mcdermott</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Biostatistics, University of Rochester</s1>
<s2>NY</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Panisset, M" sort="Panisset, M" uniqKey="Panisset M" first="M." last="Panisset">M. Panisset</name>
<affiliation><inist:fA14 i1="04"><s1>McGill Centre for Studies in Aging</s1>
<s2>Verdun, Quebec</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Friedman, J H" sort="Friedman, J H" uniqKey="Friedman J" first="J. H." last="Friedman">J. H. Friedman</name>
<affiliation><inist:fA14 i1="05"><s1>Department of Neurology, Memorial Hospital of Rhode Island</s1>
<s2>Pawtucket</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">98-0273419</idno>
<date when="1998">1998</date>
<idno type="stanalyst">PASCAL 98-0273419 INIST</idno>
<idno type="RBID">Pascal:98-0273419</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000E21</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Levodopa improves motor function without impairing cognition in mild nondemented Parkinson's disease patients</title>
<author><name sortKey="Growdon, J H" sort="Growdon, J H" uniqKey="Growdon J" first="J. H." last="Growdon">J. H. Growdon</name>
<affiliation><inist:fA14 i1="01"><s1>Massachusetts General Hospital</s1>
<s2>Boston</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kieburtz, K" sort="Kieburtz, K" uniqKey="Kieburtz K" first="K." last="Kieburtz">K. Kieburtz</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Neurology, University of Rochester</s1>
<s2>NY</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mcdermott, M P" sort="Mcdermott, M P" uniqKey="Mcdermott M" first="M. P." last="Mcdermott">M. P. Mcdermott</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Biostatistics, University of Rochester</s1>
<s2>NY</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Panisset, M" sort="Panisset, M" uniqKey="Panisset M" first="M." last="Panisset">M. Panisset</name>
<affiliation><inist:fA14 i1="04"><s1>McGill Centre for Studies in Aging</s1>
<s2>Verdun, Quebec</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Friedman, J H" sort="Friedman, J H" uniqKey="Friedman J" first="J. H." last="Friedman">J. H. Friedman</name>
<affiliation><inist:fA14 i1="05"><s1>Department of Neurology, Memorial Hospital of Rhode Island</s1>
<s2>Pawtucket</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Neurology</title>
<title level="j" type="abbreviated">Neurology</title>
<idno type="ISSN">0028-3878</idno>
<imprint><date when="1998">1998</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Neurology</title>
<title level="j" type="abbreviated">Neurology</title>
<idno type="ISSN">0028-3878</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson agent</term>
<term>Chemotherapy</term>
<term>Cognition</term>
<term>Human</term>
<term>Levodopa</term>
<term>Motricity</term>
<term>Parkinson disease</term>
<term>Psychometrics</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Lévodopa</term>
<term>Antiparkinsonien</term>
<term>Cognition</term>
<term>Motricité</term>
<term>Psychométrie</term>
<term>Chimiothérapie</term>
<term>Traitement</term>
<term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Article abstract-Objective: The objective of the study was to determine the effects of short-term levodopa administration on motor, cognitive, and psychiatric aspects of Parkinson's disease (PD). Background: The effects of levodopa on mental processes in PD are controversial. Opinions range from the claim that levodopa improves cognition to the opposite view that levodopa causes or exacerbates dementia, delusions, and hallucinations. Of the 800 idiopathic PD patients enrolled in the original DATATOP study, 387 reached the end point of functional disabilities sufficiently severe to require levodopa treatment. There were 263 men and 124 women who were comparable with regard to age, symptom duration of PD, and measures of PD severity. We compared test scores on motor performance, cognitive function, and psychiatric status before levodopa and again within 6 months after initiation of levodopa therapy. Results: Levodopa administration improved all motor functions significantly. The improvement was significantly greater in women than in men. Levodopa administration did not worsen scores on any cognitive tests, and there were quantitatively small but significant improvements in tests of frontal lobe function. Levodopa exerted only minor effects on psychiatric measures. There were small but significant decreases in scores for depression, and increases in vivid dreams and hallucinations. Conclusions: Levodopa administration for up to 6 months in dosages sufficient to improve motor function has only small effects on cognitive function and psychiatric status in mild to moderate PD patients. We conclude that motor symptoms in early PD, which result from dopamine depletion, are dissociable from cognitive functions and psychiatric status, which may be more dependent on nondopaminergic mechanisms.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0028-3878</s0>
</fA01>
<fA02 i1="01"><s0>NEURAI</s0>
</fA02>
<fA03 i2="1"><s0>Neurology</s0>
</fA03>
<fA05><s2>50</s2>
</fA05>
<fA06><s2>5</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Levodopa improves motor function without impairing cognition in mild nondemented Parkinson's disease patients</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>GROWDON (J. H.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>KIEBURTZ (K.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>MCDERMOTT (M. P.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>PANISSET (M.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>FRIEDMAN (J. H.)</s1>
</fA11>
<fA14 i1="01"><s1>Massachusetts General Hospital</s1>
<s2>Boston</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Neurology, University of Rochester</s1>
<s2>NY</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Biostatistics, University of Rochester</s1>
<s2>NY</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>McGill Centre for Studies in Aging</s1>
<s2>Verdun, Quebec</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Department of Neurology, Memorial Hospital of Rhode Island</s1>
<s2>Pawtucket</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA17 i1="01" i2="1"><s1>Parkinson Study Group</s1>
<s3>USA</s3>
</fA17>
<fA20><s1>1327-1331</s1>
</fA20>
<fA21><s1>1998</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>6345</s2>
<s5>354000075877600220</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 1998 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>29 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>98-0273419</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i2="1"><s0>Neurology</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Article abstract-Objective: The objective of the study was to determine the effects of short-term levodopa administration on motor, cognitive, and psychiatric aspects of Parkinson's disease (PD). Background: The effects of levodopa on mental processes in PD are controversial. Opinions range from the claim that levodopa improves cognition to the opposite view that levodopa causes or exacerbates dementia, delusions, and hallucinations. Of the 800 idiopathic PD patients enrolled in the original DATATOP study, 387 reached the end point of functional disabilities sufficiently severe to require levodopa treatment. There were 263 men and 124 women who were comparable with regard to age, symptom duration of PD, and measures of PD severity. We compared test scores on motor performance, cognitive function, and psychiatric status before levodopa and again within 6 months after initiation of levodopa therapy. Results: Levodopa administration improved all motor functions significantly. The improvement was significantly greater in women than in men. Levodopa administration did not worsen scores on any cognitive tests, and there were quantitatively small but significant improvements in tests of frontal lobe function. Levodopa exerted only minor effects on psychiatric measures. There were small but significant decreases in scores for depression, and increases in vivid dreams and hallucinations. Conclusions: Levodopa administration for up to 6 months in dosages sufficient to improve motor function has only small effects on cognitive function and psychiatric status in mild to moderate PD patients. We conclude that motor symptoms in early PD, which result from dopamine depletion, are dissociable from cognitive functions and psychiatric status, which may be more dependent on nondopaminergic mechanisms.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02B06</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Lévodopa</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Levodopa</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Levodopa</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Antiparkinsonien</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Antiparkinson agent</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Antiparkinsoniano</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Cognition</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Cognition</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Cognición</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Motricité</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Motricity</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Motricidad</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Psychométrie</s0>
<s5>13</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Psychometrics</s0>
<s5>13</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Psicometría</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>16</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>16</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>16</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Traitement</s0>
<s5>17</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Treatment</s0>
<s5>17</s5>
</fC03>
<fC03 i1="08" i2="X" l="GER"><s0>Aufbereiten</s0>
<s5>17</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>17</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Homme</s0>
<s5>20</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Human</s0>
<s5>20</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Hombre</s0>
<s5>20</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fN21><s1>180</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 98-0273419 INIST</NO>
<ET>Levodopa improves motor function without impairing cognition in mild nondemented Parkinson's disease patients</ET>
<AU>GROWDON (J. H.); KIEBURTZ (K.); MCDERMOTT (M. P.); PANISSET (M.); FRIEDMAN (J. H.)</AU>
<AF>Massachusetts General Hospital/Boston/Etats-Unis (1 aut.); Department of Neurology, University of Rochester/NY/Canada (2 aut.); Department of Biostatistics, University of Rochester/NY/Canada (3 aut.); McGill Centre for Studies in Aging/Verdun, Quebec/Canada (4 aut.); Department of Neurology, Memorial Hospital of Rhode Island/Pawtucket/Etats-Unis (5 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Neurology; ISSN 0028-3878; Coden NEURAI; Etats-Unis; Da. 1998; Vol. 50; No. 5; Pp. 1327-1331; Bibl. 29 ref.</SO>
<LA>Anglais</LA>
<EA>Article abstract-Objective: The objective of the study was to determine the effects of short-term levodopa administration on motor, cognitive, and psychiatric aspects of Parkinson's disease (PD). Background: The effects of levodopa on mental processes in PD are controversial. Opinions range from the claim that levodopa improves cognition to the opposite view that levodopa causes or exacerbates dementia, delusions, and hallucinations. Of the 800 idiopathic PD patients enrolled in the original DATATOP study, 387 reached the end point of functional disabilities sufficiently severe to require levodopa treatment. There were 263 men and 124 women who were comparable with regard to age, symptom duration of PD, and measures of PD severity. We compared test scores on motor performance, cognitive function, and psychiatric status before levodopa and again within 6 months after initiation of levodopa therapy. Results: Levodopa administration improved all motor functions significantly. The improvement was significantly greater in women than in men. Levodopa administration did not worsen scores on any cognitive tests, and there were quantitatively small but significant improvements in tests of frontal lobe function. Levodopa exerted only minor effects on psychiatric measures. There were small but significant decreases in scores for depression, and increases in vivid dreams and hallucinations. Conclusions: Levodopa administration for up to 6 months in dosages sufficient to improve motor function has only small effects on cognitive function and psychiatric status in mild to moderate PD patients. We conclude that motor symptoms in early PD, which result from dopamine depletion, are dissociable from cognitive functions and psychiatric status, which may be more dependent on nondopaminergic mechanisms.</EA>
<CC>002B02B06</CC>
<FD>Parkinson maladie; Lévodopa; Antiparkinsonien; Cognition; Motricité; Psychométrie; Chimiothérapie; Traitement; Homme</FD>
<FG>Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative</FG>
<ED>Parkinson disease; Levodopa; Antiparkinson agent; Cognition; Motricity; Psychometrics; Chemotherapy; Treatment; Human</ED>
<EG>Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease</EG>
<GD>Aufbereiten</GD>
<SD>Parkinson enfermedad; Levodopa; Antiparkinsoniano; Cognición; Motricidad; Psicometría; Quimioterapia; Tratamiento; Hombre</SD>
<LO>INIST-6345.354000075877600220</LO>
<ID>98-0273419</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E21 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000E21 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:98-0273419
   |texte=   Levodopa improves motor function without impairing cognition in mild nondemented Parkinson's disease patients
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

Levodopa improves motor function without impairing cognition in mild nondemented Parkinson's disease patients

Levodopa improves motor function without impairing cognition in mild nondemented Parkinson's disease patients

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri